Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST)

NCT04157127 is registered in ClinicalTrials.gov with Diakonos Oncology Corporation as lead sponsor.

NCT NCT04157127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04157127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST)
Lead sponsor
Diakonos Oncology Corporation
Phase
Phase 1
Overall status
Recruiting
Start date
August 3, 2020
Completion date
December 31, 2027
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic cancer